Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-101 single ascending dose study in LCA10-IVS26
2019-004981-16Phase 2Terminated
- Sponsor
- Editas Medicine
- Start
- Jul 2021
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EDIT-101 in Leber's congenital amaurosis type 10 (LCA10) and Fundus dystrophy, sponsored by Editas Medicine. Primary endpoint: Incidence of dose-limiting toxicity. Started Jul 2021; status: terminated.
02
Drugs
EDIT-101
03
Conditions
Leber's congenital amaurosis type 10 (LCA10)Fundus dystrophy
Beyond the preview
Go deeper on 2019-004981-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004981-16.